Bombastically yours, Peter Pompous, MD Grandiloquent Gorge, USA
Editor's Response
Dr. Pompous raises an important, and recurring, theme in his provocative letter: Does transparency in disclosing competing interests ensure objectivity and appropriateness in reporting biomedical research? To arrive at a logical response, let us first discuss disclosure and bias, and then consider how both may influence editorial decisions.
Disclosure is simply "the act of revealing something." 3 A quick search of the worldwide Web finds the term most often linked to the disciplines of law, finance, and real estate. Although brokers and attorneys have lots to reveal, physicians are also a busy bunch. Medicine accounts for nearly 60 percent of all citations with "disclosure" in the title or abstract, or as a keyword in the combined literature of science, technology, medicine, and the social sciences. 4 What exactly is revealed in medical disclosures? The fundamental purpose is to identify conflicts of interest, also called competing interests. A lucid summary appears in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals:
Public trust in the peer review process and the credibility of published articles depend in part on how well conflict of interest is handled during writing, peer review, and editorial decision making. Conflict of interest exists when an author (or the author's institution), reviewer, or editor has financial or personal relationships that inappropriately influence (bias) his or her actions [emphasis added] (such relationships are also known as dual commitments, competing interests, or competing loyalties). These relationships vary from those with negligible potential to those with great potential to influence judgment, and not all relationships represent true conflict of interest. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment. 5 Journal readers should care deeply about competing interests because, as noted in the italicized text above, they may inappropriately influence (bias) an author's actions, whether or not the author is even aware of this influence. Bias is a systematic deviation from the truth, which may occur in the collection, analysis, interpretation, publication, or review of data. 6 This "deviation from the truth" is most dangerous in studies of treatment effects because of distorted conclusions on the value-or worthlessness-of interventions. Some of the most important biases that can undermine treatment studies are as follows 7,8 :
1. Design bias occurs when the study is planned to include subjects, endpoints, comparators, or outcome measures that are more likely to yield results that support prior beliefs or expectations. 9 Examples include uncontrolled studies (case series) and studies in poorly defined populations or with unsuitable control groups. Design bias is minimized by sound study design based on principles of epidemiology. 2. Ascertainment bias is caused by studying a subject sample that does not fairly represent the larger population to which the results are to be applied. The problem is greatest with convenience or judgmental samples. Ascertainment bias is reduced by random or consecutive sampling and clear criteria for subject inclusion or exclusion. 3. Selection (allocation) bias occurs when treatment groups vary in prognosis because of different demographics, illness severity, or other baseline characteristics (measured or unmeasured). The problem is greatest for observational studies, nonrandomized trials, and for randomized trials with inadequate concealment of the allocation scheme. Selection bias is minimized when subjects are randomly allocated to treatment groups, the allocation scheme is concealed, and all subjects randomized are included in the final analyses (intention-to-treat principle). 4. Observer (measurement or information) bias can distort the way exposures or outcomes are assessed if the observer is aware of the treatment received. The problem is greatest for subjective outcomes (e.g., symptoms, satisfaction) and when the observer believes they already "know" the effect of treatment, or when they may have particular reasons for preferring one treatment to another. Observer bias is minimized through masked (blinded) assessment by independent observers. 5. Reviewer bias can lead to erroneous conclusions when an author selectively cites published studies that favor a particular viewpoint. The problem is greatest for commentaries and non-systematic (narrative or traditional) review articles, but this bias can also distort the introduction and discussion sections of original research. Reviewer bias is minimized with systematic criteria for study selection, and balanced consideration of all available evidence when drawing conclusions.
An obvious question after perusing the above is "If bias can affect research results in so many ways, isn't it a concern for all studies, not just when an author discloses a competing interest?" In fact, bias is an overriding concern for all research and is assessed routinely in the peer review process. The problem, however, is of paramount concern when financial ties exist, because industry-sponsored studies are 3 to 4 times more likely to reach pro-industry conclusions than non-sponsored research. [10] [11] Even for randomized trials, the least bias-prone research design, authors' conclusions significantly favor experimental interventions when financial competing interests are declared. 12 Recognizing the potential bias caused by financial relationships, current publishing standards mandate that authors disclose all potential conflicts of interest when submitting a manuscript for publication. The term "competing interests" is often used instead of "conflicts of interest," because the latter implies a sense of wrongdoing that might influence disclosure. 13 Financial relationships are considered the most important cause of potential bias, but other sources include personal relationships, committee service, academic competition, intellectual passions, and how one makes a living. 5, 14 Financial competing interests include employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties, and all financial and material support for the research and work. As Dr. Pompous notes, the New England Journal of Medicine used to prohibit authors from having any financial connection with a company that benefits from a drug or device discussed in an editorial or review article. As it became increasingly difficult to find authors without competing interests, the editorial staff relaxed the constraint to only significant financial interests (defined as an annual personal compensation of $10,000 or higher). 2 The purpose of disclosing all competing interests and sponsorships is to allow reviewers, editors, and readers to consider them fully when assessing the validity and appropriateness of a manuscript. A common misconception of Dr. Pompous, and others, is to assume that full disclosure and transparency in reporting will ensure that competing interests do not hinder publication. To the contrary, current standards advise that "Editors may use information disclosed in conflict of interest and financial interest statements as a basis for editorial decisions." 5 Of course, all reasonable attempts are made to "sanitize" the tone, text, and style of a manuscript before rejecting it because of bias from competing interests.
Similar to the medical profession, the financial industry has passionately pursued full disclosure. As one columnist wrote, "Transparency is well and good, but accuracy and objectivity are even better. Wall Street doesn't have to keep confessing its sins. It just has to stop committing them." 15 Until authors of biomedical manuscripts do the same, we must accept the imperfect substitutes of peer review and editorial judgment. Despite good intentions, it is not for authors to decide if a relationship causes conflict; their role is to declare, not interpret. Editors and reviewers, not authors, must ultimately determine if a competing interest causes bias.
The bottom line, however, remains caveat lector: let the reader beware-even of articles in peer-reviewed journals. But what better solution exists than to empower a volunteer army of post-publication peer reviewers (aka our readership) to voice concerns by submitting letters to the editor? Please accept, therefore, my kind personal invitation of empowerment through writing. I look forward to receiving, and publishing, your critical submissions.
Richard M. Rosenfeld, MD, MPH
Editor in Chief
